請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47473
標題: | 分子片段組合之新穎結構設計於抗血管內皮生長因子受體藥物開發 A Fragment-based De Novo Design of VEGFR2/3 Inhibitors |
作者: | Yi-Syuan Huang 黃薏璇 |
指導教授: | 曾宇鳳 |
關鍵字: | 血管內皮生長因子受體,基於片段,新穎結構設計,片段效率,第二型磷酸激酶,抑制劑, VEGFR,Fragment-based,De-Novo Design,Group Efficiency,Type II Kinase Inhibitors, |
出版年 : | 2010 |
學位: | 碩士 |
摘要: | Vascular endothelial growth factor receptor 2 and 3 (VEGFR-2/3) are important protein kinases targets for angiogenesis and lymphangiogenesis of cancer treatments. Most “Type I kinase inhibitors” are ATP competitive while “Type II kinase inhibitors” target the inactive form of kinase by interacting with a hydrophobic allosteric site created by the outstretched DFG domain. Designing compounds with good inhibition, selectivity, specificity and solubility is challenging for kinase inhibitors. It would be beneficial to start with a known drug and use its physicochemical properties and binding mode as a template.
In this study, we developed a fragment-based de novo design strategy to design novel type II VEGFR-2/3 inhibitors based on sorafenib (Nexavar®) , a known Type II kinase inhibitor. Three steps were employed in the design of new VEGFR-2/3 inhibitors. First, the inactive VEGFR-2/3 binding pocket, where sorafenib binds, was divided into an allosteric site, linker spacer, and ATP binding site. Second, potential active site fragments were selected from the Scifinder database and used to flood the binding site. Eight docked poses for each fragment were selected from the ensemble, located in the ATP binding and the allosteric site, and each fragment was prioritized based on a group efficiency score and selected via drug-likeness filters. The final step generates a series of new compounds by linking fragments that have an average of three alternative connections per linker. The new compound was prescribed a bound conformation similar to that of the known ligand (preserving key receptor - ligand interactions) and analyzed. To test the performance of our method, we were able to re-generate sorafenib and its analogues and another type II inhibitor – nilotinib (Tasigna®) automatically from a total combination of 1330 fragments for each segment of the binding site; eight docked poses for each fragment and average 3 linker attachment points for each linker. |
URI: | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47473 |
全文授權: | 有償授權 |
顯示於系所單位: | 生醫電子與資訊學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 4.69 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。